ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antibodies"

  • Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting

    Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies

    Earl Sands1, Alan J. Kivitz2, Wesley DeHaan Ph.D.1, Lloyd Johnston1 and Takashi Kei Kishimoto1, 1Selecta Biosciences, Watertown, MA, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose:   Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
  • Abstract Number: 2136 • 2017 ACR/ARHP Annual Meeting

    Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis

    Adam Schiffenbauer1, Sara Faghihi-Kashani2, Terrance P. O'Hanlon1, Willy Flegel3, Sharon Adams3, Ira N. Targoff4, Chester V. Oddis5,6, Rohit Aggarwal7,8, Lisa G Rider1, Steven R. Ytterberg9, Lisa Christopher-Stine10, Sonye K. Danoff11, Paul F. Dellaripa12,13, Ejaz Shamim14, Andrew Mammen15 and Frederick W Miller16, 1Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 2Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, 3Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 4VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, 6Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, 8Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, 9Rheumatology, Mayo Clinic, Rochester, MN, 10Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 11Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, 12Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 13Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, 149. Department of Neurology, Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, 15Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, 16Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD

    Background/Purpose: Interstitial lung disease (ILD) is a frequent complication and a major contributor to mortality and morbidity in polymyositis and dermatomyositis (PM/DM). Prior studies have…
  • Abstract Number: 2139 • 2017 ACR/ARHP Annual Meeting

    Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis

    Eri Watanabe1, Takahisa gono1, Shinji Watanabe1, Hiroki Yabe1, Masataka Kuwana2 and Chihiro Terai1, 1Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: PM and DM are inflammatory myopathies, sometimes complicated by interstitial lung disease (ILD), myocarditis, arthritis, and malignancies. The intensity of immunosuppressive therapies depends on…
  • Abstract Number: 2318 • 2017 ACR/ARHP Annual Meeting

    Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy

    Eileen Pagano1, Myriam Kline2 and B. Anne Eberhard3, 1Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 2Biostatistics Unit, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, 3Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY

    Background/Purpose: Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-a). It is known to be effective and often used in the…
  • Abstract Number: 2876 • 2017 ACR/ARHP Annual Meeting

    Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome

    Tiezheng Yuan1, Michelle Petri2, Alan N. Baer3 and H. Benjamin Larman1, 1Pathology (Immunology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 3Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: An unbiased and comprehensive approach to the analysis of Sjögren’s syndrome (SS) antibody repertoires would provide important data on its pathogenesis. Phage ImmunoPrecipitation sequencing…
  • Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting

    Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients

    Robert W. Georgantas III1, Melanie Ruzek2, Justin Wade Davis1, Feng Hong1, Elizabeth Asque1, Kenneth Idler1, Heikki T. Mansikka1, Benoit Guerette1 and Jeffrey F. Waring1, 1AbbVie Inc., North Chicago, IL, 2Immunology Discovery, AbbVie, Worcester, MA

    Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…
  • Abstract Number: 2841 • 2016 ACR/ARHP Annual Meeting

    Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus

    Luis F. Perez-Garcia1, Irving Omar Estevez-Garcia1, Mariana Moreno Ramirez1, Javier Loaiza Felix1, Ricardo Marquez-Velasco2, Pedro Iturralde3, Luis H. Silveira4,5 and Luis M. Amezcua-Guerra1, 1Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 2Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 3Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 4Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, 5Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico

    Background/Purpose: Long QT syndrome (LQTS) is characterized by an abnormal QT corrected (QTc) interval prolongation that is associated with increased risk of sudden death. Studies…
  • Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting

    ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial

    Mark C. Genovese1, Michael Weinblatt2, Jacob A Aelion3, Heikki T. Mansikka4, Paul M. Peloso4, Kun Chen4, Yihan Li4, Ahmed A. Othman4, Amit Khatri4, Nasser S. Khan4 and Robert J. Padley4, 1Stanford University Medical Center, Palo Alto, CA, 2Brigham and Women’s Hospital, Boston, MA, 3West Tennessee Research Institute, Jackson, TN, 4AbbVie Inc., North Chicago, IL

    Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…
  • Abstract Number: 2875 • 2016 ACR/ARHP Annual Meeting

    Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups

    Caroline Grönwall1, Uta Hardt1, Iva Gunnarsson2, Gregg J. Silverman3 and Elisabet Svenungsson1, 1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, 3Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Natural IgM autoantibodies have been proposed to have protective properties, and decreased levels of IgM to phosphorylcholine (PC) in SLE are associated with higher…
  • Abstract Number: 726 • 2016 ACR/ARHP Annual Meeting

    Comparison of Infliximab Immunogenicity in Inflammatory Arthritis Versus Inflammatory Bowel Disease Patients in Routine Clinical Practice

    Marianne Guirgis1, Melanie Favre dit Jeanfavre2, Charles Benaim3, Matthieu Perreau4, Pierre Michetti5, Michel Maillard1 and Pascal Zufferey6, 1gastroenterology, Lausanne, Switzerland, 2DAL, RHU, Lausanne, Switzerland, 3DAL, MPR, Lausanne, Switzerland, 4Medecine /CHUV, Immunology, Lausanne, Switzerland, 5La Source-Beaulieu, Lausanne, Switzerland, 6Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland

    Background/Purpose: Infliximab is a biological agent frequently used for inflammatory arthritis (IA) such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis as well as for the inflammatory…
  • Abstract Number: 2905 • 2016 ACR/ARHP Annual Meeting

    Predictors of Poor Hand Function in Systemic Sclerosis

    Ashraf Raslan1 and Vivien Hsu2, 1Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, 2Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ

    Background/Purpose: Systemic Sclerosis (SSc) is a progressive systemic disease that can lead to variable degrees of morbidity and disability. Hand dysfunction in SSc patients [1]…
  • Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting

    Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort

    Anna Hoffmann-Vold1, Anders Heiervang Tennøe2, Oyvind Midtvedt2, May Brit Lund3, Torhild Garen2, Fadi El-Hage4, Trond Mogens Aalokken5, Eli Taraldsrud4 and Øyvind Molberg2, 1Division of Rheumatology, Oslo University Hospital, Oslo, Norway, 2Rheumatology, Oslo University Hospital, Oslo, Norway, 3Respiratory Medicine, Oslo University Hospital, Oslo, Norway, 4Oslo University Hospital, Oslo, Norway, 5Radiology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
  • Abstract Number: 3225 • 2016 ACR/ARHP Annual Meeting

    Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis

    Mark C. Genovese1, Michael Weinblatt2, Heikki T. Mansikka3, Paul M. Peloso3, Kun Chen3, Yihan Li3, John Liu3 and Robert J. Padley3, 1Stanford University Medical Center, Palo Alto, CA, 2Brigham and Women’s Hospital, Boston, MA, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: ABT-122 is a dual variable domain immunoglobulin (DVD-Ig™) that targets human tumor necrosis factor-α (TNF-α) and interleukin-17A (IL-17A). The object was to investigate the…
  • Abstract Number: 1011 • 2016 ACR/ARHP Annual Meeting

    Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome

    Joseph LaConti1, Fanny Kippelen2, Rohit Aggarwal3 and Dana P. Ascherman4, 1Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL, 2Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, 3Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL

    Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome Background/Purpose: Idiopathic inflammatory myopathy (IIM) is an…
  • Abstract Number: 3243 • 2016 ACR/ARHP Annual Meeting

    Intestinal Microbial Dysbiosis in SLE Is Linked to Elevated IgA and Induction of Autoimmunity

    Doua F. Azzouz1, Lelise Getu2, Celine Anquetil1, Jill P. Buyon3 and Gregg J. Silverman3, 1Medicine, NYU School of Medicine, New York, NY, 2Department of Medicine, New York University School of Medicine, New York, NY, 3Medicine, New York University School of Medicine, New York, NY

    Background/Purpose: SLE is a complex multifactorial systemic autoimmune disease, which has been attributed to poorly understood interactions between genetic and environmental factors. Recent reports have…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology